These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 22519361)

  • 21. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
    Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Lastiri GG; Rivera-Márquez H; Villasis-Keever MA; Del Angel VW; Díaz FC; López-Aguilar E
    Arch Med Res; 2008 Aug; 39(6):601-6. PubMed ID: 18662592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
    Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis.
    Yamaguchi A; Saito Y; Takekuma Y; Sugawara M
    Support Care Cancer; 2023 Dec; 32(1):58. PubMed ID: 38145979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
    Vladimirova LY; Mitashok IS; Storozhakova AE; Kalabanova EA; Svetitskaya YV; Kabanov SN
    Vopr Onkol; 2015; 61(4):653-5. PubMed ID: 26571839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
    Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
    Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
    Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
    Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
    Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
    Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A; Malaguti P
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
    Navari RM
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.